496807-64-8

Basic information

• Product Name: EN460
• Synonyms: EN460
• CAS NO: 496807-64-8
• Molecular Formula: C22H12ClF3N2O4
• Molecular Weight: 460.79
• Mol File: 496807-64-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 583.8±60.0 °C(Predicted)
• Appearance: /
• Density: 1.48±0.1 g/cm3(Predicted)
• PKA: 2.66±0.25(Predicted)
• CAS DataBase Reference: EN460(CAS DataBase Reference)
• NIST Chemistry Reference: EN460(496807-64-8)
• EPA Substance Registry System: EN460(496807-64-8)

Safety Data

• Hazardous Substances Data: 496807-64-8(Hazardous Substances Data)

Usage

Description

EN460 is a selective inhibitor of ERO1a, a protein involved in the regulation of cellular redox homeostasis. It effectively prevents ERO1 re-oxidation, which is crucial for maintaining the balance of reduced and oxidized proteins within cells. This property makes EN460 a valuable tool in the study and potential treatment of various diseases and conditions related to cellular redox imbalance.

Uses

Used in Pharmaceutical Research:
EN460 is used as a research tool for studying the role of ERO1a in cellular redox homeostasis. By inhibiting ERO1a, researchers can gain insights into the mechanisms underlying various diseases and conditions associated with redox imbalance, such as cancer, neurodegenerative diseases, and cardiovascular diseases.
Used in Anticancer Applications:
EN460 is used as a potential therapeutic agent for cancer treatment. By inhibiting ERO1a, it can disrupt the redox balance in cancer cells, leading to the inhibition of tumor growth and progression. This selective targeting of ERO1a may offer a novel approach to cancer therapy, with the potential for fewer side effects compared to conventional treatments.
Used in Drug Delivery Systems:
EN460 can be incorporated into drug delivery systems to improve its bioavailability and therapeutic efficacy. By using various carriers, such as organic and metallic nanoparticles, the delivery of EN460 to target cells can be enhanced, potentially leading to more effective treatment outcomes.